Perspective Therapeutics, Inc. CATX 深 沪
已收盘 08-07 16:00:00 美东时间
3.00
+0.030
+1.01%
华盛通- 最 高3.06
- 今 开3.03
- 成交量 104.58万股
- 最 低 2.94
- 昨 收 2.97
- 总市值 3.42亿
- 52周最高 6.16
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 1.955
- 委 比 -64.33%
- 总股本 1.14亿
- 历史最高 37.90
- 量 比 0.84
- 振 幅 4.04%
- 历史最低 1.60
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At European Society Of Medical Oncology Congress 2026
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted f...
07-18 00:24
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining around 100 points on Tuesday. Shares of Telefonaktiebolaget LM Ericsson – ADR (NASDAQ:ERIC) fell sharply in pre-market trading following second-quarter results. ERIC reported quarterly earnings of 13 cents per share whic...
07-14 20:03
Perspective Doses First Brain Tumor Patient in Radiopharmaceutical Study, Expands Cancer Drug Trial to Meningioma Patients
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced
06-03 18:33
Perspective Therapeutics Announces That The First Patients Were Dosed In Two New Cohorts Of Phase 1/2a Studies In Neuroendocrine Tumors And Solid Tumors, Respectively
The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2
05-18 18:32
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
05-05 19:42
美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价
今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元
04-21 11:25
Perspective Therapeutics Reports 72% Of Patients Alive Without Disease Progression In Early Cancer Trial, Says 43% Of Patients Show Tumor Response With New Radiotherapy Treatment
Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced updated interim
04-20 18:12
美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
